glp-1 agonist adverse effects glp 1 risks Peptide/GLP-1 Complications: 11 Hidden Risks and Side You Must Know The current significance and prospects

162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction

[DOI] [PubMed] [Google Scholar] 20.Thethi TK, Pratley R, Meier JJ

Patients with type 2 diabetes who are about to begin, or who have recently begun, taking a GLP-1 drug should have a baseline dilated eye examination to determine their level of DR

Best for: People with insulin resistance or pre-diabetes who want a well-established, affordable metabolic support medication

[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Filippatos TD, Elisaf MS

New York: Springer New York